Why Remission—Not Just Relief—Changes Ketamine Care

The Shift From 'Less Bad' to Actually Better

A growing consensus among psychiatrists is challenging the long-standing, often unspoken acceptance of partial recovery in treatment-resistant depression (TRD). Writing in Psychiatric Times in April 2026, clinicians argue that the bar for depression care needs to be raised—from simply reducing symptoms to achieving full remission. That distinction matters enormously for the millions of patients who have cycled through antidepressants without ever feeling truly well.

Treatment-resistant depression is typically defined as a failure to respond adequately to at least two different antidepressant trials at therapeutic doses. For these patients, the treatment landscape has historically been bleak: augmentation strategies, combination therapies, ECT, and—more recently—ketamine-based interventions. What the new clinical framing demands is that providers stop celebrating a 30–40% reduction in depressive symptoms as a win, and instead keep pushing toward endpoints that actually restore quality of life.

This isn't a minor philosophical shift. It has real consequences for how treatment plans are structured, how long ketamine protocols are maintained, and how success is measured along the way.

Where Oral Ketamine Tablets Fit In This New Framework

Ketamine has earned a well-documented place in TRD treatment, largely on the strength of IV infusion data and, more recently, the FDA-approved intranasal esketamine (Spravato). But oral ketamine tablets occupy a distinct and increasingly relevant niche—one that aligns well with a remission-focused, long-term treatment model.

Here's why: achieving remission in TRD rarely happens after a single acute intervention. The research consistently shows that patients who respond to ketamine often need ongoing maintenance dosing to sustain those gains. IV infusions, while potent, are logistically intensive and expensive—typically $400–$800 per session, administered in a clinical setting, with limited insurance coverage. For patients in a maintenance phase, that model is difficult to sustain over months or years.

Oral ketamine tablets offer a practical middle path. With bioavailability typically ranging from 20–30% (compared to nearly 100% for IV), tablets require higher absolute doses to achieve comparable plasma levels—but they can be taken at home, on a schedule that fits the patient's life, under a prescribing clinician's oversight. For remission-oriented care, this matters. A patient who needs dosing two or three times per week over six to twelve months is far more likely to stay adherent with a tablet protocol than with repeated clinic visits.

Tablets also allow for fine-grained dose titration. Unlike infusions—where dose adjustments require rescheduling and clinical supervision—oral formulations can be incrementally adjusted between appointments, giving clinicians a more responsive tool for chasing a remission endpoint rather than settling for a response plateau.

It's worth distinguishing tablets from the closely related sublingual troches and lozenges. Troches dissolve under the tongue, allowing some absorption through the oral mucosa before the remainder is swallowed. This produces a faster onset and slightly higher bioavailability than a swallowed tablet. For some patients, the faster onset is therapeutically meaningful—and for others, it's a tolerability drawback, producing more pronounced dissociative effects. Tablets, absorbed primarily through the GI tract, tend to have a slower, smoother onset curve, which some patients find easier to manage, particularly at higher maintenance doses.

Balancing Efficacy, Side Effects, and Patient Priorities

The Psychiatric Times piece also emphasizes something oral ketamine patients will recognize immediately: the negotiation between therapeutic benefit and side effect tolerance is central to long-term care. Clinicians are urged to take patient-reported side effects seriously and factor individual priorities into treatment decisions rather than defaulting to a one-size-fits-all protocol.

For oral ketamine users, the most commonly reported side effects include transient dissociation, nausea, dizziness, and—with chronic use—potential concerns around urinary tract health and psychological dependence. A remission-focused framework doesn't mean pushing doses to the ceiling regardless of tolerability. It means finding the therapeutic window where a patient can sustain treatment long enough to reach and maintain remission.

Practically, this often looks like starting at a conservative dose (many outpatient programs begin around 1–2 mg/kg for oral formulations, though protocols vary), assessing response over four to eight weeks, and titrating upward only if the tolerability profile supports it. Patients who experience significant nausea may do better with tablets taken with a light meal; those prone to dissociative side effects may benefit from evening dosing when they can rest afterward.

The push toward remission also reinforces the importance of combining ketamine with psychotherapy. Ketamine creates a window of neuroplasticity—often described as a period of enhanced psychological flexibility following dosing—that appears to amplify the benefits of concurrent therapeutic work. Patients using oral tablets at home have an opportunity to structure therapeutic activities, journaling, or scheduled therapy sessions around their dosing windows, something that's harder to operationalize around clinic-based infusions.

What This Means for Patients Navigating TRD

If you're using oral ketamine tablets as part of a TRD treatment plan, this evolving clinical framework offers both validation and a call to higher expectations. Validation, because ketamine's role in TRD is no longer fringe—it's increasingly central to how forward-thinking clinicians approach patients who haven't responded to conventional antidepressants. And higher expectations, because the goal shouldn't be surviving your depression more comfortably. It should be remission.

Concretely, that means having frank conversations with your prescriber about where you are on the response-to-remission spectrum, whether your current dosing schedule is optimized for maintenance, and what adjunctive supports—therapy, lifestyle interventions, complementary medications—might help close the gap. It also means advocating for yourself if you've plateaued at 'somewhat better' and your provider hasn't revisited the protocol recently.

The oral tablet format is well-suited to this kind of long-arc, iterative treatment. Its flexibility, relative affordability, and at-home accessibility make it a realistic vehicle for the kind of sustained, remission-focused ketamine care that psychiatry is increasingly pointing toward.

Source: Psychiatric Times — Different Approaches for Management of Treatment Resistant Depression (April 2026)